Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Reply to thread

Message

Agree. People forget that 50% of all diabetes profits go to Lilly. The type 2 market is extremely competitive and Jardiance is doing well but certainly not growing as expected. The entire SGLT2 market is flat. Nobody's fault really, just too many drugs chasing a limited # of patients.

[QUOTE="anonymous, post: 6109116"] Agree. People forget that 50% of all diabetes profits go to Lilly. The type 2 market is extremely competitive and Jardiance is doing well but certainly not growing as expected. The entire SGLT2 market is flat. Nobody's fault really, just too many drugs chasing a limited # of patients. [/QUOTE]

Name

Verification